Utah Based Recursion News Today

Biotech company Recursion used AI and supercomputers to predict an unprecedented number of chemical reactions that could lead to effective drugs.

Nvidia (NASDAQ:NVDA) price spring up Wednesday, on word the chipmaker will invest $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm’s artificial intelligence models for drug discovery, the companies said Wednesday. ...

Nvidia is investing in Recursion, which uses AI models to identify new therapies and offers those models to its partners, including Roche and Bayer.

Nvidia is investing in Recursion, which uses AI models to identify new therapies and offers those models to its partners, including Roche and Bayer.

Nvidia is investing in Recursion, which uses AI models to identify new therapies and offers those models to its partners, including Roche and Bayer.

Recursion Pharma (RXRX) shares jumped for the second straight session on Tuesday to double its value this month amid interest in AI led drug discovery. Read more here.

ADVERTISEMENT ADVERTISEMENT 5 Firms Lead Trio of Biotech IPOs Raising $721M Combined Law360 (April 16, 2021, 6:02 PM EDT) -- Three biotechnology firms went public to receptive investors Friday after raising $721 million combined in initial public offerings guided by five law firms, led by an upsized offering by Recursion Pharmaceuticals Inc., which uses artificial intelligence to develop rare disease treatments. Recursion, advised by Wilson Sonsini Goodrich & Rosati PC, raised $436.4 million a...